Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.

Robert G Hart1, Silvina B Tonarelli, Lesly A Pearce

  • 1Department of Medicine, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA. hartr@uthscsa.edu

Stroke
|June 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Location, size, and risk factors of incident covert brain infarcts in patients with acute non-cardioembolic ischemic stroke: PACIFIC-STROKE trial.

European stroke journal·2025
Same author

Hemorrhagic Infarction Does Not Worsen Functional Outcomes in Noncardioembolic Ischemic Stroke: Secondary Analysis From PACIFIC-STROKE.

Stroke·2025
Same author

Dual versus single antiplatelet therapy in patients with non-cardioembolic acute ischemic stroke and baseline MRI.

European stroke journal·2025
Same author

Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial.

The Lancet. Neurology·2025
Same author

Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease.

Stroke·2025
Same author

Hemorrhagic Transformation in Noncardioembolic Acute Ischemic Stroke: MRI Analysis From PACIFIC-STROKE.

Stroke·2024

Intracerebral hemorrhages (ICHs) are a rare but serious risk of antithrombotic drugs. Managing blood pressure and anticoagulation intensity can reduce ICH occurrence in patients.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Antithrombotic therapies are crucial for preventing thrombotic events but carry a risk of intracerebral hemorrhage (ICH).
  • Approximately 7000 ICHs occur annually in the US due to antithrombotic use.
  • This review focuses on ICH in patients on long-term anticoagulation or antiplatelet therapy.

Purpose of the Study:

  • To review the incidence of ICH in patients using antithrombotic therapies.
  • To identify risk factors and predictors of ICH in this patient population.
  • To provide evidence-based recommendations for reducing ICH risk.

Main Methods:

  • Literature review of recent reports on ICH incidence during anticoagulation.
  • Analysis of risk factors including patient age, blood pressure, and medication combinations.

Related Experiment Videos

  • Evaluation of the impact of blood pressure control and anticoagulation intensity.

    • Main Results:

    • ICH rates during oral anticoagulation are reported between 0.3% and 0.6% annually.
    • Key risk factors include advanced age, hypertension, high anticoagulation intensity, and prior cerebral ischemia.
    • Combining antiplatelet agents or using aspirin with clopidogrel increases ICH risk; blood pressure lowering reduces ICH frequency.

    Conclusions:

    • ICH is an uncommon yet potentially fatal complication of antithrombotic therapy, especially in patients with prior stroke.
    • Maintaining an international normalized ratio (INR) ≤3.0, controlling hypertension, and avoiding combined aspirin-warfarin therapy can decrease ICH frequency.